SU5614 / Pfizer - LARVOL DELTA

VEGF-D Is Enriched in the Human Lung Microvascular Niche and Improves Vascular Integrity During Acute Lung Injury (ATS 2024) - "The blockage of VEGFR2 through either siRNA or pharmacological inhibitor SU5614 attenuates the impact of VEGF-D. This study highlights the cell-cell crosstalk signals in lung microvascular niche between healthy and diseased individuals and determines a novel and potentially therapeutic role of VEGF-D in improving lung vascular integrity."

Acute Lung Injury • Acute Respiratory Distress Syndrome • Chronic Obstructive Pulmonary Disease • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • ANGPT1 • SLIT2 • TNFA • VEGFC • VEGFD

Downregulation of NAGLU in VEC Increases Abnormal Accumulation of Lysosomes and Represents a Predictive Biomarker in Early Atherosclerosis. (PubMed, Front Cell Dev Biol) - "However, the application of selective VEGFR2 and ERKs inhibitors, SU5614 and PD98059, respectively, could reverse the abnormal lysosomal storage caused by NAGLU knockdown. These results indicated that downregulation of NAGLU in HUVEC increases the abnormal accumulation of lysosomes and may be a potential biomarker for the diagnosis of EAS."

Biomarker • Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • APOE • HBEGF